Astrazeneca (AZN) Long-Term Debt Repayments (2022 - 2026)

Astrazeneca has reported Long-Term Debt Repayments for 5 years, with the latest figure at -$2.5 billion in Q2 2026.

• On a quarterly basis, Long-Term Debt Repayments fell 20325.0% year-over-year to -$2.5 billion in Q2 2026; TTM through Jun 2026 was -$4.5 billion, a 120.54% decrease from a year earlier, with the FY2025 full-year figure at -$2.0 billion, up 56.38% from the prior year.
• Long-Term Debt Repayments was -$2.5 billion for Q2 2026 at Astrazeneca, down from -$2.0 million in the prior quarter.
• The five-year high for Long-Term Debt Repayments was -$2.0 million in Q1 2026, with the low at -$2.6 billion in Q2 2024.
• Average Long-Term Debt Repayments over 5 years is -$985.6 million, with a median of -$632.5 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Long-Term Debt Repayments tumbled 50000.0% in 2023, then surged 99.8% in 2025.
• Over 5 years, Long-Term Debt Repayments stood at -$1.3 billion in 2022, then decreased by 12.05% to -$1.4 billion in 2023, then surged by 99.64% to -$5.0 million in 2024, then plunged by 40080.0% to -$2.0 billion in 2025, then slipped by 22.0% to -$2.5 billion in 2026.
• The last three Long-Term Debt Repayments figures came in at -$2.5 billion (Q2 2026), -$2.0 million (Q1 2026), and -$2.0 billion (Q4 2025), per Business Quant data.